Alpha1 Antitrypsin Deficiency

Study Outline

This study is:

Approximately 3 years
Phase III
Safety and Efficacy of two dose regimes of the study drug
Weekly infusions

To find out if this trial is suitable for you please register below, or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

Eligibility & Requirements

18 – 70 years old
Diagnosis of Alpha1 Antitrypsin Deficiency with evidence of emphysema
No flare up of the chest in the last 5 weeks prior to the first visit
No cancer in last 5 years

What's Involved

You will be required to come once a week for 3 years for treatment including health checks to the Institute for Respiratory Health at Level 2, 6 Verdun Street, Nedlands WA 6009
CT scans of your lungs will be required on 5 occasions throughout the trial

I have been diagnosed with:
Name*
First Last
Phone*
Email*
Address
Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country
Receive our newsletter?
- Yes
Name
This field is for validation purposes and should be left unchanged.

Current Clinical Trials

Alpha1 Antitrypsin Deficiency

GTi1201

INS1007-301

D9180C00002

PACE

Bayesian Evidence-Adaptive Treatment in Cystic Fibrosis (BEAT CF)

Cystic Fibrosis

ARO-ENaC-1001

IPF Study

IM027-040